- Home
- VLYPO vs KALA Comparison
VLYPO vs KALA Comparison
Compare VLYPO & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VLYPO
- KALA
- Stock Information
- Founded
- VLYPO N/A
- KALA 2009
- Country
- VLYPO United States
- KALA United States
- Employees
- VLYPO 3732
- KALA 38
- Industry
- VLYPO Major Banks
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- VLYPO Finance
- KALA Health Care
- Exchange
- VLYPO Nasdaq
- KALA Nasdaq
- Market Cap
- VLYPO N/A
- KALA 26.2M
- IPO Year
- VLYPO N/A
- KALA 2017
- Fundamental
- Price
- VLYPO $25.02
- KALA $3.72
- Analyst Decision
- VLYPO
- KALA Strong Buy
- Analyst Count
- VLYPO 0
- KALA 2
- Target Price
- VLYPO N/A
- KALA $13.50
- AVG Volume (30 Days)
- VLYPO N/A
- KALA 56.4K
- Earning Date
- VLYPO N/A
- KALA 05-14-2025
- Dividend Yield
- VLYPO N/A
- KALA N/A
- EPS Growth
- VLYPO N/A
- KALA N/A
- EPS
- VLYPO N/A
- KALA N/A
- Revenue
- VLYPO N/A
- KALA N/A
- Revenue This Year
- VLYPO N/A
- KALA N/A
- Revenue Next Year
- VLYPO N/A
- KALA N/A
- P/E Ratio
- VLYPO N/A
- KALA N/A
- Revenue Growth
- VLYPO N/A
- KALA N/A
- 52 Week Low
- VLYPO N/A
- KALA $2.92
- 52 Week High
- VLYPO N/A
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- VLYPO 53.10
- KALA 46.95
- Support Level
- VLYPO $25.06
- KALA $3.67
- Resistance Level
- VLYPO $25.20
- KALA $4.16
- Average True Range (ATR)
- VLYPO 0.13
- KALA 0.31
- MACD
- VLYPO -0.03
- KALA 0.08
- Stochastic Oscillator
- VLYPO 27.66
- KALA 53.89
About VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.